Know earlier if ICI treatment is working with Signatera
During treatment with immune-checkpoint inhibitors (ICI) for advanced or metastatic cancers, you want answers to critical questions as soon as possible. Is treatment working? Is the tumor truly progressing? Is there a need to change or reinitiate treatment? Signatera is a personalized tumor-informed assay for ultrasensitive detection of molecular residual disease (MRD) that helps you find answers to these questions earlier than traditional tests and imaging. Dive deeper.